Aytu BioScience (NASDAQ:AYTU) reported quarterly sales of $23.50 million which beat the analyst consensus estimate of $20.90 million by 12.44 percent. This is a 58.13 percent increase over sales of $14.86 million the same period last year.
Cellectar Awarded $2.0M Phase II NIH SBIR Grant To Support Pivotal Study Of Iopofosine I-131 In Waldenstrom’s Macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a
